Technology
Health
Biotechnology

Cyclacel Pharmaceuticals

$0.5499
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.0049 (0.90%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell CYCC and other stocks, options, ETFs, and crypto commission-free!

About CYCC

Cyclacel Pharmaceuticals, Inc. Common Stock, also called Cyclacel Pharmaceuticals, is a clinical-stage biopharmaceutical company. Read More It uses cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The company builds a diversified biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

Employees
14
Headquarters
Berkeley Heights, New Jersey
Founded
1996
Market Cap
9.37M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
70.30K
High Today
$0.5585
Low Today
$0.52
Open Price
$0.55
Volume
83.51K
52 Week High
$1.87
52 Week Low
$0.51

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Medical
Cancer Prevention
Pharmaceutical
US

CYCC Earnings

-$0.20
-$0.10
$0.01
$0.11
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.